All In MedTech

FDA Clearance Tracker · P150040

VISUMAX FEMTOSECOND LASER

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Sep 13, 2016 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Sep 13, 2016

Approved

Time to decision

319 days

Received Oct 30, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150040
Device name
VISUMAX FEMTOSECOND LASER
Applicant location
Dublin, CA
Received
Oct 30, 2015
Decided
Sep 13, 2016
Decision
Approved
Supplements
23 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code OTL

FDA's approval statement

As written in FDA's record.

Approval for the VisuMax Femtosecond Laser. This device is indicated for use in small incision lenticule extraction (SMILE) for the reduction or elimination of myopia >= -1.00 D to <= -8.00 D, with <= -0.50 D cylinder and MRSE <= -8.25 D in the eye to be treated in patients who are 22 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change of <= 0.50 D MRSE.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code OTL (Femtosecond laser system for refractive correction).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Carl Zeiss Meditec, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.